Table 2. Comparisons between patients receiving and not receiving adequate empirical treatment for bacteremia with P. aeruginosa.

	Patients receiving adequate empirical treatment (n = 151)				Patients receiving inadequate empirical treatment (n = 36)
	N	median	%	IQR	N	median	%	IQR	p-value
Demographics
Age (years)		66		50–75		67		58–79	0.160
Male gender	99		65.6%		29		80.6%		0.082
Underlying conditions
Charlson comorbidity index		3		2–4		3		2–5	0.159
Intravenous drug use	15		9.9%		2		5.6%		0.412
Immunosuppression	68		45.0%		21		58.3%		0.151
Solid organ transplant	2		1.3%		1		2.8%		0.476
Allogenic stem cell transplant	11		7.3%		2		5.6%		1.000
Autologous stem cell transplant	4		2.6%		1		2.8%		1.000
Neutropenia at diagnosis	31		20.5%		0		0.0%		0.001
Clinical presentation
PITT bacteremia score		1		0–2		1		0–2	0.997
Septic shock	16		10.6%		4		11.1%		1.000
ICU admission	53		35.1%		18		50.0%		0.098
Mechanical ventilation	9		6.0%		4		11.11%		0.280
Microbiological features
Number of positive bloodcultures	2			1–4		2		2–3	0.721
Polymicrobial sepsis	55		36.4%		15		41.7%		0.559
MDR P. aeruginosa	7		4.6%		5		13.9%		0.057
XDR P. aeruginosa	1		0.66%		0		0.0%
Origin of bacteremia									0.215
Urinary tract	33		21.9%		9		25.0%
Unknown	27		17.9%		12		33.3%
Vascular catheter	31		20.5%		3		8.3%
Respiratory tract	22		14.6%		9		25.0%
Abdominal	14		9.3%		2		5.6%
Skin/soft tissue	11		7.3%		1		2.8%
Surgical site infection	6		4.0%		0		0.0%
Bone/joint	4		2.7%		0		0.0%
Pancreaticobiliary	3		2.0%		0		0.0%
Outcome
Death during hospital stay	22		14.6%		11		30.6%		0.024
Death attributable to bacteremia	18		11.9%		10		27.8%		0.017

Significant p-values are printed in bold; ICU: intensive care unit, MDR: multidrug-resistant, XDR: Extensively drug-resistance